logo-loader

Kintara Therapeutics announces first international site activation in its Phase 2/3 clinical trial for glioblastoma multiforme

Published: 11:45 30 Nov 2021 EST

Kintara Therapeutics -
Between 150 to 200 patients are expected to be enrolled in the Kintara arm of the study at over 40 sites in the US and Canada with potential to increase this total to 65 clinical trial centers worldwide

Kintara Therapeutics (NASDAQ:KTRA) Inc has announced its first international site activation in its Global Coalition for Adaptive Research (GCAR) registrational Phase 2/3 clinical trial for glioblastoma multiforme (GBM).

The treatment arm was activated in Canada at Toronto’s Sunnybrook Health Sciences Centre. Kintara’s treatment arm is also actively recruiting at 30 US sites.

The trial is a patient-centered, Phase 2/3 adaptive platform trial that evaluates multiple therapies for patients with newly-diagnosed and recurrent GBM.

Between 150 to 200 patients are expected to be enrolled in the Kintara arm of the study at over 40 sites in the US and Canada with the potential to increase this total to 65 clinical trial centers worldwide, according to the company.

READ: Kintara presents updates on two Phase 2 clinical studies at the 2021 Society for Neuro-Oncology annual meeting

The Kintara treatment arm joined the GBM AGILE study in January 2021, and is already active at 31 sites in the US and Canada, according to Timothy Cloughesy, a professor at the neurology and molecular and medical pharmacology program at the University of California, Los Angeles and principal investigator for the GBM AGILE study.

"This international clinical site, which we expect to be the first of many international sites, demonstrates the ability of GCAR's GBM AGILE platform trial to materially accelerate the clinical development timelines for the company,” Cloughsey told investors in a statement.

"The entire Kintara team remains excited by the pace at which our treatment arm is being executed in the study," Robert Hoffman, Kintara's CEO added. "With 31 sites already active, including our first international site, we are delighted to witness GCAR's exceptional clinical trial execution capabilities that drew us to participate in this exciting and highly efficient registrational study."

San Diego-based Kintara is dedicated to the development of novel cancer therapies for patients with unmet medical needs.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

4 hours, 48 minutes ago